Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
BioFocus plc
Drug discovery alliance to cover multiple targets
September 24th, 2004
BioFocus plc (BIO) and Galapagos Genomics NV, Europe's leading target discovery company, announced that they have entered into a multi-target collaboration. The collaboration will combine BioFocus' integrated drug discovery engine with Galapagos' extensive expertise in target validation and cellular models of human disease. Under the terms of the agreement, Galapagos will provide validated drug targets and BioFocus will discover and progress potential drugs to the lead compound stage. Galapagos will further develop these compounds into novel drugs for treating diseases of unmet medical need. The collaboration will be focused on...
Source: Food & Drug Law Weekly (2004-09-24)
|
